Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cetirizine-induce cholestasis.

D G Fong1, P Angulo, L J Burgart

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA.

Journal of Clinical Gastroenterology
|October 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: is proton pump inhibitor use associated with worse outcomes in patients with liver abscesses?

Alimentary pharmacology & therapeutics·2018
Same author

Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis.

Alimentary pharmacology & therapeutics·2018
Same author

Editorial: Betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease.

Alimentary pharmacology & therapeutics·2015
Same author

An update on primary sclerosing cholangitis:from pathogenesis to treatment.

Minerva gastroenterologica e dietologica·2013
Same author

Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study.

Alimentary pharmacology & therapeutics·2013
Same author

Interactions between chronic liver disease and inflammatory bowel disease.

Inflammatory bowel diseases·2013
Same journal

GLP-1 Receptor Agonists and Hepatic Encephalopathy in Cirrhosis: A Protective Signal Requiring Cancer and Nutritional Phenotyping.

Journal of clinical gastroenterology·2026
Same journal

Endoscopic Incisional Therapy for Benign Esophageal Strictures: A Systematic Review and Meta-Analysis.

Journal of clinical gastroenterology·2026
Same journal

International Consensus Statements on the Use of Topical Endoscopic Hemostatic Powders in the Treatment of Acute Gastrointestinal Bleeding.

Journal of clinical gastroenterology·2026
Same journal

Do Risk Factors for Reflux Symptoms After Peroral Endoscopic Myotomy Necessarily Increase the Occurrence of Postoperative Gastroesophageal Reflux?

Journal of clinical gastroenterology·2026
Same journal

Subgroup Stratification by Regimen, Geography, and Population Is Necessary to Validate Nitazoxanide-based Helicobacter pylori Eradication Therapy.

Journal of clinical gastroenterology·2026
Same journal

The Impact of Glucagon-Like Peptide 1 Receptor Agonists Versus Diabetes Mellitus on Endoscopic Procedures: A Case-Control Study From a Large Tertiary Care Health System.

Journal of clinical gastroenterology·2026
See all related articles

Cetirizine, an allergy medication, can cause liver injury. A case study suggests cetirizine-induced cholestasis, a liver condition, may occur even when hydroxyzine metabolism is not implicated.

Area of Science:

  • Pharmacology
  • Hepatology
  • Allergology

Background:

  • Cetirizine is a widely used H1-receptor antagonist for allergic conditions.
  • Previous studies noted minor, transient liver enzyme elevations in less than 2% of patients on cetirizine.
  • The drug is a human metabolite of hydroxyzine.

Observation:

  • A 28-year-old male without prior liver disease developed cholestasis.
  • The patient had taken cetirizine daily for two years.
  • Ursodeoxycholic acid and hydroxyzine were used for treatment.

Findings:

  • The case suggests cetirizine can induce cholestasis, a specific type of drug-induced liver injury.
  • Improvement with hydroxyzine suggests this metabolite pathway is not the cause in this instance.

Related Experiment Videos

  • Cetirizine is identified as a potential cause of drug-induced cholestasis.

    • Implications:

    • Clinicians should consider cetirizine as a potential cause of cholestasis.
    • This case highlights the importance of monitoring liver function in patients on long-term cetirizine therapy.
    • Further research may be needed to elucidate the exact mechanisms of cetirizine-induced hepatotoxicity.